RBS2418

DRUG4 trials

Conditions

Advanced CancerAdvanced Colorectal CancerAdvanced Unresectable Hepatocellular CarcinomaExpanded Access in Pancreatic CancerMetastatic Colorectal Cancer

Phase 1

Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

RecruitingNCT05270213

Riboscience, LLC.Advanced Cancer

Start: 2022-07-11End: 2027-12-31Target: 164Updated: 2025-12-19

Phase 2

Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer

RecruitingNCT06824064

Riboscience, LLC.Advanced Colorectal Cancer, Metastatic Colorectal Cancer

Start: 2025-01-17End: 2027-12-01Target: 150Updated: 2026-05-18

Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma

RecruitingNCT07175441

Riboscience, LLC.Advanced Unresectable Hepatocellular Carcinoma

Start: 2026-04-10End: 2027-08-01Target: 220Updated: 2026-04-24

Unknown Phase

Expanded Access RBS2418 Treatment

NCT05683470

Riboscience, LLC.Expanded Access in Pancreatic Cancer

Updated: 2024-02-21

Journal of Clinical Oncology2025-05-28

Correlation of baseline ENPP1 and cGAS expression in advanced solid tumors with intratumoral immune activation and clinical outcomes after treatment with the first-in-class oral ENPP1 inhibitor RBS2418, alone or in combination with pembrolizumab.

Journal of Clinical Oncology2024-06-011 citations

169P Immunomodulatory effects of RBS2418, an oral ENPP1 inhibitor in combination with pembrolizumab in checkpoint-refractory metastatic adrenal cancer

Immuno-Oncology Technology2022-12-014 citations

195TiP A first-in-human, phase I a/b dose escalation and expansion study to evaluate RBS2418 as monotherapy and in combination with pembrolizumab in subjects with advanced unresectable, recurrent or metastatic tumors

Immuno-Oncology Technology2022-12-011 citations

RBS2418

Sponsors

Conditions

Phase 1

Phase 2

Unknown Phase

Related Papers